Replies to post #156187 on Biotech Values

[DewDiligence]

A typical gym conversation. Bought low, sold high. These conversations are generally as truthful as people's recaps of whether they "won" in Las Vegas.

What stood out about the conversation is how little some biotech investors know about the stocks they invest in—e.g. what Provenge is and is not (a cure for all caners). That was my reason for posting it.